BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 29, 2018--
Inc. (NYSE American: BTX), a clinical-stage biotechnology company
focused on degenerative diseases, today announced that Brian M. Culley,
Chief Executive Officer of BioTime will be presenting at the LD
Micro 11th Annual Main Event Investor Conference on
December 5th, 2018 at 8am Pacific Time at the Luxe Sunset
Boulevard Hotel in Los Angeles, CA.
Interested parties can access a live audio webcast on the Events
and Presentations section of BioTime’s website. An archived
presentation will be available on the website for 30 days. Conference
updates can be found on the LD
Micro website and directly via Twitter (@theLDMicro).
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.